Chemoradiation for elderly patients (≥ 65 years) with esophageal cancer: a retrospective single-center analysis

Philipp Linde1,2*, Markus Mallmann1,2, Anne Adams3, Simone Wegen1,2, Johannes Rosenbrock1,2, Maike Trommer1,2, Simone Marnitz1,2, Christian Baues1,2 and Eren Celik1,2

Abstract

Background: Present studies on the efficacy and safety of curative chemoradiation therapy (CRT) with esophageal cancer reflect heterogeneous results especially in elderly patients. The aim of this study was to evaluate the toxicity and efficacy of CRT in patients ≥ 65 years. In a cohort, the focus centered around treatment-related toxicity (CTCAE Grade > 3), overall survival as well as progression free survival, comparing these rates in-between patients older than 70 years to those younger than 70 years.

Methods: A total of 67 patients older than 65 years (34 (50.7%) were older than 70 years) met the inclusion criteria for retrospective analysis (period from January 2013 to October 2017). Treatment consisted of radiotherapy and chemotherapy with carboplatin/paclitaxel or fluorouracil (5-FU)/cisplatin with the intention of neoadjuvant or definite chemoradiation. A sum of 67 patients received CRT (44 (65.6%) patients in neoadjuvant, 23 (34.4%) in definite intent). Of these, 22 and 12 patients were older than 70 years (50% and 52.2% in both treatment groups, respectively). Median age was 71 years and patients had a good physical performance status (ECOG 0: 57.6%, ECOG 1: 27.3%). Median follow-up was 24 months. Most patients had advanced tumor stages (T3 stage: n = 51, 79.7%) and nodal metastasis (N1 stage: n = 54, 88.5%). A subgroup comparison was conducted between patients aged ≤ 70 years and > 70 years.

Results: In severe (CTCAE Grade 3–5) toxicities (acute and late), no significant differences were observed between both patient groups (< 70 years vs. > 70 years). 21% had acute grade 3 events, 4 patients (4%) had grade 4 events, and two patients (3%) had one grade 5 event. Late toxicity after CRT was grade 1 in 13 patients (22%), grade 2 in two (3%), grade 3 in two (3%), grade 4 in four (7%), and grade 5 in one (2%). Median overall survival (OS) of all patients was 30 months and median progression-free survival (PFS) was 16 months. No significant differences were seen for OS (32 months vs. 25 months; p = 0.632) and PFS (16 months vs. 12 months; p = 0.696) between older patients treated with curative intent and younger ones. Trimodal therapy significantly prolonged both OS and PFS (p = 0.005; p = 0.018), regardless of age.

Conclusion: CRT in elderly patients (≥ 65 years) with esophageal cancer is feasible and effective. Numbers for acute and late toxicities can be compared to cohorts of younger patients (< 65 years) with EC who received the same...
Background
In 2020, 604,100 cases of esophageal cancer (EC) were newly diagnosed; the disease caused 544,076 deaths worldwide [1]. In Germany, EC makes up about 3.5 percent of all cancer deaths in men and 1.2 percent in women [2].

Squamous cell carcinomas (SCCs) represent the majority of histopathologic esophageal cancers in Western countries, but the incidence of adenocarcinomas (ACs) has increased significantly [3]. Treatment consisting of chemoradiation therapy (CRT) and surgery is considered the multimodal standard of care for patients with locally advanced EC [4–7].

Here, treatment of elderly EC patients can be challenging as they can present poor physiologic (performance) status as well as competing comorbidities. Treatment decisions should not only take into account patients’ age, but also their functional status, risk of treatment-related morbidities, life expectancy, and patients’ preference [8, 9]. Previously, a significant association between comorbidity, treatment tolerance and overall survival could be described based on a study of a series of 109 patients aged ≥70 treated with definite CRT (dCRT) [10].

Another retrospective single-center analysis showed that treatment of elderly patients with definite or neoadjuvant CRT can lead to significantly higher toxicity and far less favorable outcome [11]. The accessible evidence mirrors the general applicability of trial results to the elderly population, although often debarred—or at least underrepresented—in clinical trials [12].

To close this gap and examine CRT in elderly EC patients, we performed this retrospective single-center analysis from our institution investigating trimodal therapy and dCRT regimes in elderly patients with EC with a focus on acute and late toxicities, overall and progression free survival.

Methods
We conducted a retrospective analysis of 67 patients aged ≥65 years with EC (cT1-4, any N, any M) who were treated either with neoadjuvant or definite CRT between January 2013 and October 2017 at our cancer center. Due to the time period covered by this study and practice-changing procedures, dose prescription, chemotherapy regimens and radiation techniques are different. Inclusion criteria were newly diagnosed histologically proven SCC or AC of the esophagus, patient age ≥65 years and neoadvant or definite CRT using conventional (anterior–posterior (APPA) fields, 3D-conformal multi-field, or intensity-modulated radiotherapy (IMRT)) techniques. Patients were excluded if they were treated for recurrent disease or if they had received prior CRT. We excluded incomplete records where radiotherapy was stopped prematurely and not applied up to the total prescribed dose. A systematic investigation of patients’ clinical charts and reports was performed in order to obtain patient and treatment characteristics, reported acute and late toxicities, and treatment-related outcomes.

Chemoradiation
For radiotherapy planning, patients were simulated supine and immobilized with a universal/wing board for mid thoracic to distal esophageal tumors or long mask for upper esophageal tumors. Contrast medium was administered both intravenously and orally, provided there were no contraindications (such as risk of aspiration or allergy). The gross tumour volume (GTV) was identified on the pre-chemotherapy extent of the disease, using the initial positron emission tomography in combination with a computed tomography (PET/CT) scan and endoscopy report. The entire esophageal wall, including any disease that extended through the wall, was contoured as GTV as well as any (PET/CT)-avid or enlarged lymph nodes. The clinical target volume (CTV) encompassed the peri-esophageal lymph nodes, mediastinal lymph nodes and the submucosal spread longitudinally along the esophagus. This required a 3–4 cm expansion on the GTV superiorly and inferiorly and a 1.0–1.5 cm radial expansion. The planning target volume (PTV) was generated adding 0.7 cm isotropically.

Radiotherapy was administered once a day, five times a week, except weekends and holidays, with a daily dose of 1.8 Gy. The total doses administered to PTV were 50.4 Gy and a sequential boost of 9 Gy to the GTV in dCRT and 41.4 Gy in nCRT, respectively.

Patients were assigned to chemotherapy (n=65, 97%) according to a treatment plan based on performance status, comorbidity, and the presence of specific contraindications to the planned agents, which was developed by a multidisciplinary tumour board and finally prescribed by the treating radiation oncologist. Patients who were to receive taxane-based nCRT were planned for four administrations; five to six applications were targeted in the definitive setting. In 87% of patients, intravenous

Keywords: Carcinoma, Esophageal cancer, Chemoradiation, Elderly, Toxicity
chemotherapy consisted of either cycles of carboplatin/paclitaxel (Carb/TAX; carboplatin [AUC 2 mg/mL per min] combined with paclitaxel [50 mg/m² body-surface area], weekly, five times) or two courses of cisplatin/5-fluorouracil (CDDP/5FU; cisplatin [75 mg/m² body-surface area] on the first day combined with 5-fluorouracil [1000 mg/m²] continuous infusion daily for four days).

The cisplatin-containing chemotherapy regimen was administered after adequate i.v. prehydration, manitol and i.v. antiemetics (5HT3 antagonists and dexamethasone), followed by i.v. posthydration. Taxane-based therapy was applied under premedication to prevent hypersensitivity reactions (dexamethasone, dimetinden maleate and H2 antagonists). Additional antiemetics (5HT3 antagonists, corticosteroids, dimenhydrinate and metoclopramide) were used at a patient’s request to treat persistent nausea. During CRT, a complete blood count and serum chemistry test, including creatinine clearance were done once a week, more frequently if needed.

We considered dose reduction or treatment de-escalation of chemotherapy if grade 3 to 4 haematological toxicity occurred. An individual decision on dose reduction or discontinuation of chemotherapy was also made in case severe radiation-related toxicity occurred.

**Monitoring under radiochemotherapy and accompanying supportive measures**

Acute treatment toxicity was assessed weekly during radiotherapy and daily during chemotherapy. If clinically indicated, toxicity was monitored more frequently. The documentation was standardized using the valid Common Terminology Criteria for Adverse Events (CTCAE) version in the respective period. Supportive care included management of pain, nausea or other side effects, nutritional counselling, enteral or parenteral nutrition, and supportive hospitalization if necessary.

**Follow-up**

After CRT, all patients received follow-up appointments at our department, the first one 8–10 weeks after the end of treatment, followed by further appointments every three to six months afterwards during the first year. In addition, patients also received their oncological follow-up or surgery (when nCRT was performed) in the departments of medical oncology or visceral surgery. Radiooncological aftercare included medical history and clinical examination. We reviewed follow-up imaging (mostly computertomography and endoscopy results) of the tumour region (in most cases the scans were signed up by the medical oncologist) and scheduled them if they have not been performed yet. After the first year of follow-up, if no progressive or recurrent disease occurred, appointments were extended to every 6–12 months until disease progression or death; earlier if patients had complaints. Patients, medical oncologists, and their general practitioners were encouraged to report complications after CRT and were contacted if they missed a scheduled follow-up appointment. Recurrent disease was documented by histological biopsy if accessible. In case of missing information, the database of the University Hospital of Cologne was checked for information about survival or recurrence.

**Statistical analysis and ethical considerations**

A person who is 65 years of age or older is often referred to as "elderly" [13, 14]. Three groups were created for analysis: Total collective, patients younger than 70 years, patients older than 70 years [15]. A subgroup comparison was conducted between patients aged ≤ 70 years and > 70 years. The latter were compared with each other. Survival data were estimated according to the Kaplan–Meier method [16]. OS was defined as the interval from the first day of treatment to death or to the last follow-up time point still alive. PFS was calculated from the first day of treatment until death or diagnosis of relapse (local or distant metastases) or last follow-up alive. Univariate analyses were performed using log rank testing and a Cox regression analysis [17]. A p-value of <0.05 was defined as statistically significant. Acute and late toxicity was scored retrospectively according to CTCAE V.5.0 [18]. Performance status was scored according to the ECOG index [19]. Calculations and data management were performed with SPSS®-statistics software v.26.0.0.1.

The study was conducted in accordance with the Declaration of Helsinki in its latest version. Due to the retrospective nature, from the point of view of the local ethics committee, there is no professional consultation obligation for the North Rhine physicians according to § 15 para. 1 of the professional code of conduct. All patients gave written informed consent before the start of treatment.

**Results**

Median follow-up for the entire cohort was 24 months. Median age of the 67 patients in our cohort at the start of therapy was 71 years (range 65–82), 19 patients were female, 48 were male. 34 patients (50.7%) had SCC, 33 patients (49.3%) AC. The majority presented with ECOG index between 0 and 1 (57.6% vs. 27.3%), T3 stage (n=51; 79,7%) and N1 stage (n=54; 88,5%). Most were treated with nCRT (n=44; n=22>70 years) and received surgery; 23 patients were treated with definite
intent (n = 12 > 70 years). For detailed patient and treatment characteristics see Table 1.

All patients completed radiotherapy with the RT dose we initially prescribed.

Chemotherapy
58 of our 67 patients received concurrent platinum-taxane-based chemotherapy, four were treated with CDDP/5FU, two patients received taxol and one carboplatin monotherapy. Two patients did not receive any chemotherapy based on the interdisciplinary assessment of the treatment team.

Treatment-related toxicity

Acute
Severe adverse events (CTCAE Grade 3–5 acute toxicity) were found in 20 cases; nine in the group older than 70 years. More specifically, 14 patients (21%) had grade 3 events, 4 patients (4%) had grade 4 events and two patients (3%) had one grade 5 event. Most reported grad 3 and 4 events were (odyno-)dysphagia, nausea, and fatigue. Patients with grade 5 toxicity presented as follows: 80 years, female, ECOG 3, CCI 2, cT3, SCC, and dCRT (taxol mono) and 68 years, male, ECOG 2, CCI 2, cT4, SCC, and dCRT (CDDP/5FU), respectively. Grade 5 toxicity in both patients was related to haematotoxicity. In detail, there were no significant differences in treatment-related acute toxicity between the groups younger vs. older than 70 years.

Late
Grade 3 late toxicity (or higher) was found in seven of 58 evaluable cases; two in the group older than 70 years. In general, maximum late toxicity after CRT was grade 1 in 13 patients (22%), grade 2 in two (3%), grade 3 in two (3%), grade 4 in four (7%), and grade 5 in one (2%); mainly (odyno-)dysphagia. The patient with grade 5 toxicity presented as follows: 67 years, male, ECOG 2, CCI 5, cT3, SCC, and dCRT (Carb/TAX). Grade 5 toxicity was related to fistula. Again, there were no significant differences in treatment-related late toxicity between the groups younger vs. older than 70 years. For detailed analysis of acute and late toxicity see Tables 2 and 3.

Survival analysis
No significant differences were seen for median overall survival (32 months vs. 25 months; p = 0.632) and progression-free survival (16 months vs. 12 months; p = 0.696) between older patients (>70 years) treated with curative intent and younger ones (<=70 years), see Figs. 1 and 2, respectively. The median OS of all patients ≥ 65 years was 30 months and

| Table 1 | Patient and treatment characteristics (n) |
|---------|------------------------------------------|
| **Sex** | **Grading** |
| Female | 19 (28.4%) | 1 |
| Male | 48 (71.6%) | 2 |
| Age | 3 | 25 |
| Median | 71 y | Unknown |
| Mean | 71.6 y | T-stage |
| Range | 65–82 y | 1 |
| ECOG | 2 | 10 |
| 0 | 38 | 3 |
| 1 | 18 | 4 |
| 2 | 6 | Tx/Unknown |
| 3 | 4 | N-stage |
| Unknown | 1 | 0 |
| Tumor site | 1 | 54 |
| Cervical | 4 | 2 |
| Upper thoracic | 11 | 3 |
| Middle thoracic | 19 | Nx/Unknown |
| Lower thoracic | 33 | M-stage |
| Histology | 0 | 63 |
| Adeno | 33 | 1 |
| SCC | 34 | Mx/Unknown |
| AJCC/UICC stage¹ | SCC | Adeno |
| II | 4 | |
| III | 23 | 25 |
| IVA | 2 | 2 |
| IVB | 1 | 2 |
| Unknown | 4 | 4 |
| Chemotherapy | RT technique |
| Neoadjuvant | 44 | APPA (two-field) |
| Definite | 23 | 3D-CRT (multi-field) |
| Agents | | IMRT |
| Platinum-taxane-based | 58 | Unknown |
| Others | 9 | |
| Charlson score² | SCC | Adeno |
| ≤ 1 | 27 | 25 |
| > 1 | 7 | 8 |

Adeno adenocarcinoma, IMRT intensity modulated radiation therapy, RT radiation therapy, SCC squamous cell carcinoma, 3D-CRT three-dimensional conformal radiation therapy, Unknown Due to the retrospective character of the study, y years
¹ 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction, ²The final score was calculated for each patient by considering all comorbid conditions present with the exclusion of EC
Table 2. Acute treatment related toxicities according to CTCAE v5.0 for both patient groups, absolute number of patients ($n=67$)

| CTC grade | 0 | 1 | 2 | 3 | 4 | 5 |
|-----------|---|---|---|---|---|---|
|           | ≤ 70 y % | > 70 y % | ≤ 70 y % | > 70 y % | ≤ 70 y % | > 70 y % | ≤ 70 y % | > 70 y % | ≤ 70 y % | > 70 y % |
| Hematological | 3 | 9.1 | 7 | 20.6 | 9 | 27.3 | 10 | 29.4 | 15 | 45.5 | 13 | 38.2 | 3 | 9.1 | 2 | 5.9 | 2 | 6.1 | 1 | 2.9 | 1 | 3.0 | 1 | 29 |
| Odynodysphagia | 20 | 60.6 | 19 | 55.9 | 3 | 9.1 | 10 | 29.4 | 3 | 9.1 | 2 | 5.9 | 6 | 18.2 | 3 | 8.8 | 1 | 30 | 0 | 0 | 0 | 0 | 0 |
| Nausea | 30 | 90.9 | 28 | 82.4 | 2 | 6.1 | 6 | 17.6 | 1 | 3.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Skin toxicity | 21 | 63.6 | 22 | 64.7 | 10 | 30.3 | 11 | 32.4 | 2 | 6.1 | 0 | 0 | 0 | 0 | 1 | 2.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fatigue | 30 | 90.9 | 24 | 70.6 | 2 | 6.1 | 7 | 20.6 | 1 | 3.0 | 2 | 5.9 | 0 | 0 | 1 | 2.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiopulmonary | 32 | 97.0 | 34 | 100.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inappetence/ weight loss | 32 | 97.0 | 32 | 94.1 | 1 | 3.0 | 1 | 2.9 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 29 | 87.9 | 30 | 88.2 | 2 | 6.1 | 3 | 8.8 | 2 | 6.1 | 0 | 0 | 0 | 0 | 1 | 2.9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

y years
the median PFS was 16 months, see Figs. 3 and 4, respectively. The median OS for SCC patients was 19 months vs. 32 months for AC \((p=0.679)\).

nCRT showed significantly advantages in OS and PFS compared to dCRT (43 months vs. 17 months; \(p=0.005\); 16 months vs. 7 months; \(p=0.018\)), see Figs. 5 and 6, respectively. In the univariate Cox regression model, nCRT significantly affected OS and PFS \((p=0.008; p=0.023)\), too. The trend shown is independent of age. ECOG index 0–1

**Table 3** Late treatment related toxicities according to CTCAE v5.0 for both patient groups, absolute number of patients \((n=58)\)

|                     | All grades |                | Grade 3–5 |               |
|---------------------|------------|----------------|-----------|---------------|
|                     | n          | n              | n         | %             |
|                     | \(\leq70\) y | \(>70\) y      | \(\leq70\) y | \(>70\) y     |
| Odynodyspagia       | 28         | 30             | 5         | 17.8          |
| Nausea              | 28         | 30             | 0         | 0             |
| Skin toxicity       | 28         | 30             | 0         | 0             |
| Fatigue             | 28         | 30             | 0         | 0             |
| Cardiopulmonary     | 28         | 30             | 0         | 0             |
| Inappetence/weight loss | 28    | 30             | 0         | 0             |
| Fistula             | 28         | 30             | 1         | 3.6           |
| Other               | 27         | 30             | 0         | 0             |

y years

**Fig. 1** Overall survival for patients younger or older than 70 years. \(n=67\). Log Rank (Mantel-Cox): \(p=0.632\)
was one parameter significantly affecting both OS and PFS ($p = 0.001$; $p = 0.003$); G3-staged carcinomas showed significantly improved PFS ($p = 0.044$) for patients $< 70$ years.

Detailed results of univariate Cox regression analysis are demonstrated in Table 4.

**Discussion**

With the overall increase in average life expectancy, the number of elderly EC patients is increasing year by year. In this study, we evaluated the toxicities and the outcome of nCRT and dCRT for EC in elderly patients younger than 70 years (minimum was 65 years of age) compared with patients out of the same cohort but older than 70 years.

30 years ago, the usefulness and compatibility of definite concurrent chemoradiation and its advantages in terms of survival compared to radiation alone were already demonstrated in randomized trials [20]. In comparison to surgery alone, nCRT significantly improved the survival rate of patients with curative therapy approach for esophageal or GEJ carcinoma by further developments in the last decade [6].

Unfortunately, elderly patients were underrepresented in the CROSS trial. The median patient age in the original study was 60 years. Several data suggest that trimodal therapy for the elderly is feasible, but without impact on survival benefit for patients over 70 years [21, 22]. Maybe this finding should be carefully considered, as the benefit of neoadjuvant therapy for patients with advanced T or N category is well established [23, 30].

Nevertheless, elderly patients who formally meet the criteria for neoadjuvant treatment followed by esophagectomy should be considered for nCRT depending on their individual comorbidities [24, 25, 27].

Our data show that curative CRT of patients with any EC older than 70 years result in no significant differences regarding acute and late toxicities as in patients younger than 70 years. The results of Lu et al. indicated that the treatment of patients with EC aged $\geq 75$ years with CRT was effective and an age of 75 years did
not affect the frequency of adverse events [26]. A pooled analysis of three clinical trials could show that patients \( \geq 70 \) years with advanced EC benefitted from the addition of platinum-based chemotherapy with respect to tumour regression, symptomatic response, and survival, but without increased acute or late toxicities, too [27]. Song et al. analyzed elderly patients (age \( \geq 70 \) years) treated with platinum-taxane-based CRT resulting in tolerable toxicities, too [28]. Grade \( \geq 3 \) leukopenia was observed, and the most common non-hematologic toxicity was esophagitis with grade 3 and 4 toxicities. Also Zhao et al. presented data of 86 patients \( \geq 70 \) years receiving single- or double-agent concurrent CRT with slightly higher acute toxicities in the double-agent cohort (grade \( \geq 2 \) neutropenia and gastrointestinal reactions) [29]. Our data agree that patients with SCC, proximal tumor location, and age less than 70 years are at increased risk for fistulae during or after chemoradiation [30]. This group of patients may benefit from more intensive therapy monitoring, follow-up, and radiomics [31].

The retrospective comparisons of Münch et al. [32, 33] between the two common chemotherapy regimes (CDDP/5FU or Carb/TAX) underline our results in relation to the low moderate acute and late toxicities due to chemotherapy in our cohort of elderly patients. Carb/TAX is considered more tolerable than platinum-fluoropyrimidine [34–36].

However, our data reveal that the risk of significant myelotoxicity does not increase with patients’ age [28]. Remarkably, in a large-scale study of the CROSS regimen in patients over 75 years of age, longer OS was observed after nCRT followed by surgery compared with surgery alone or dRCT, with no differences in postoperative mortality [37]. In contrast, Haefner and Minsky et al. found no difference in outcomes between cohorts receiving nCRT followed by surgery and dCRT stating that age and comorbidities should not be evaluated alone for the
decision for dCRT versus nCRT followed by surgery [38, 39].

Qiu et al. could show that in a cohort of 855 elderly EC patients, the prognosis of elderly patients treated with chemotherapy was better than that of treatment without, regardless of whether the patients were treated with surgery or radiotherapy, including comparable toxicities [40]. Mantziari et al. pointed out that fewer elderly patients are being offered nCRT followed by surgery compared to younger ones, even though the histological response is at least as good as in younger patients. Not surprisingly, after trimodal therapy, complications (cardiovascular > pulmonal) are more common in older patients [41]. Here, patient selection should be performed carefully. nCRT followed by surgery may offer a survival benefit for elderly patients with incomplete clinical response to treatment [42].

Age per se should not be the sole factor for or against trimodal therapy [43–46]. Scoring systems like P-POSSUM or O-POSSUM and predictive models as published by Steyerberg et al. and, more recently, by the International Esodata Study group should be considered by stratifying our patients for more or less aggressive therapy regimens [47–50].

Patient-reported outcome measurement, quality of life (QOL) scoring and individual co-morbidities and the known pharmacokinetic properties and modes of action in the elderly must be also taken into consideration when stratifying the different modalities of therapy for elderly patients with EC [51–56].

More than half of our patient cohort were treated with 3D-CRT. Münch and Haefner compared 3D-CRT and modern radiation techniques such as IMRT for nCRT followed by surgery or dCRT in patients with esophageal cancer [37, 57]. Interestingly, no significant differences were found in terms of PFS and OS; still it is important to note that the use of modern radiotherapy techniques in patients undergoing nCRT was associated with a lower dose to organs at risk [37].
Of note, our retrospective analysis had some limitations. Treatment adherence is one of the most important endpoints in the treatment of frail or elderly patients. It should be recorded after all patients who have started chemoradiation with curative intent have been registered. Unfortunately, due to the retrospective nature of the study, we are not able to capture the total number of the collective, which we have to cite as a major limitation. It is therefore clear that our results should be interpreted with caution. Secondly, we were unable to adjust for multiple potential confounders and detect differences in this study. Finally, each elderly patient had an individual comorbidity and there was a lack of information regarding comorbidities, which may have introduced bias in the assessment of the benefit of therapy.

Nevertheless, our results underline both the feasibility and the need for modified inclusion concepts in older esophageal cancer patients. Further large prospective studies or randomized trials are still needed in order to validate the optimal modification strategy for CRT and establishment for age-based standards in elderly EC patients. Studies should consider imperative factors such as a patient's life expectancy, comorbidity, and a geriatric assessment. Wishes and expectations of the individual patient should also be included in the decision-making process. Key criteria should be post-therapy mortality and morbidity rates, rates of acute and late side effects of (C)RT, and short- and long-term effects in regard of QOL.

**Conclusion**
Chemoradiation offers a feasible therapy for elderly patients. Curative CRT of patients with any EC older than 70 years results in comparable rates of acute and late toxicities as in patients <70 years. Age at treatment initiation alone should not be a determining factor alone, rather an individual's functional status, risk of treatment-related morbidities, life expectancy and their preference should be included. With improvements in tumour staging and treatment options, similar outcomes to younger cohorts appear to be achievable.
Fig. 6 Overall survival for nCRT and dCRT. n = 67. Log Rank (Mantel-Cox): p = 0.018

Table 4 Univariate Cox regression analysis. HR > 1 indicates a greater risk for the group > 70y; HR < 1 indicates a smaller risk for the group > 70y

| Parameter                  | OS HR [95% CI] | p-value | PFS HR [95% CI] | p-value |
|----------------------------|----------------|---------|-----------------|---------|
| Treatment Regimen (nCRT vs. dCRT) | 0.399 [0.203; 0.785] | 0.008 | 0.477 [0.252; 0.902] | 0.023 |
| Age > 70 y vs. ≤ 70 y       | 0.850 [0.433; 1.666] | 0.636 | 0.891 [0.493; 1.610] | 0.701 |
| Sex (Female > 70 y vs. ≤ 70 y) | 0.782 [0.205; 2.982] | 0.719 | 0.605 [0.168; 2.173] | 0.441 |
| (Male > 70 y vs. ≤ 70 y)    | 0.773 [0.340; 1.759] | 0.539 | 1.032 [0.511; 2.083] | 0.931 |
| ECOG (2–3 vs. 0–1)        | 3.825 [1.738; 8.416] | <0.001 | 3.096 [1.460; 6.565] | 0.003 |
| T-stage (> 70 y vs. ≤ 70 y) |                |        |                  |        |
| T3                        | 0.958 [0.429; 2.140] | 0.917 | 0.973 [0.496; 1.908] | 0.936 |
| Grading (> 70 y vs. ≤ 70 y) |                |        |                  |        |
| G2                        | 0.379 [0.133; 1.081] | 0.070 | 0.487 [0.204; 1.164] | 0.105 |
| G3                        | 2.328 [0.819; 6.619] | 0.113 | 2.585 [1.025; 6.520] | 0.044 |
| Histology (> 70 y vs. ≤ 70 y) |                |        |                  |        |
| SCC                       | 0.462 [0.174; 1.227] | 0.121 | 0.454 [0.172; 1.193] | 0.109 |
| AC                        | 1.968 [0.625; 6.197] | 0.248 | 1.495 [0.632; 3.536] | 0.360 |

HR Hazard ratio, CI Confidence interval, OS Overall survival, PFS Progression-free survival, y years
Abbreviations
3D-CRT: 3-Dimensional conformal radiotherapy; AC: Adenocarcinoma; Carb/ TAX: Carboplatin and paclitaxel; CDDP/5FU: Cisplatin and 5-Fluorouracil; dCRT: Definitive chemoradiotherapy; EC: Esophageal cancer; GEJ: Esophagogastric-junction; GTV: Gross target volume; Gy: Gray; IMRT: Intensity-modulated radiotherapy; nCRT: Neoadjuvant chemoradiation therapy; OS: Overall survival; PET/CT: Positron emission tomography/computed tomography; PFS: Progression-free survival; PTV: Planning target volume; SCC: Squamous cell carcinoma; QOL: Quality of life.

Acknowledgements
Special thanks to Fabia Bertram for her support in proofreading as a native speaker.

Author contributions
EC and MM developed the study design and collected data. Formal analysis was done by AA, PL and EC made substantial contributions to conception and design of the study, interpreted data, and revised the manuscript; PL drafted the manuscript initially. MM, SW, MT, CB and SM contributed significantly to the discussion and interpretation of the results. All authors read and approved the final manuscript.

Funding
Open-Access funding enabled and organized by Projekt DEAL. We acknowledge support for the Article Processing Charge from the DFG (German Research Foundation, 491454339). No other funds, grants, or other support was received.

Availability of data and materials
The present data are summarized in this paper. The complete dataset can be retrieved from the authors upon formal request from interested readers.

Declarations
Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki in its latest version. Due to the retrospective nature, from the point of view of the local ethics committee, there is no professional consultation obligation for the North Rhine physicians according to § 15 para. 1 of the professional code of conduct.

Consent for publication
All patients gave written informed consent before the start of treatment.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Radiation Oncology, Cyberknife and Radiation Therapy, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Kerpener St 62, 50937 Cologne, Germany. 2. Center for Integrated Oncology (CIO), University Hospital of Cologne, Faculty of Medicine and University of Cologne, Kerpener St 62, 50937 Cologne, Germany. 3. Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University of Cologne, Kerpener St 62, 50937 Cologne, Germany.

Received: 29 January 2022 Accepted: 14 November 2022 Published online: 17 November 2022

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.
2. Various: Krebs in Deutschland für 2015/2016. Gemeinsame Publikation des Zentrums für Krebsregisterdaten und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V, vol. 12. Berlin: Robert Koch-Institut Berlin, 2019.
3. Domper Arnal MJ, Ferrández Arenas Á, Lanas AÁ. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933–43.
4. Eyck BM, van Lanschot JJB, Hulshof MCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39(18):1995–2004.
5. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
6. Ochi M, Murakami Y, Nishihuchi I, et al. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma. J Radiat Res. 2021;62(1):142–8.
7. Burmeister BH, Smithers BM, Gebki V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–68.
8. Won E, Ilson DH. Management of localized esophageal cancer in the older patient. Oncologist. 2014;19:367–74.
9. Molena D, Stern M, Blackford AL, et al. Esophageal cancer treatment is underutilized among elderly patients in the USA. J Gastrointest Surg. 2017;21:126–36.
10. Tougeron D, di Fiore F, Thureau S, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with esophageal cancer. Br J Cancer. 2008;99:1586–92.
11. Walter F, Böckle D, Schmidt-Hegemann NS, et al. Clinical outcome of elderly patients (≥70 years) with esophageal cancer undergoing definitive or neoadjuvant radiochemotherapy: a retrospective single center analysis. Radiat Oncol. 2018;13:93.
12. Chen RC, Royce T, Extremann M, et al. Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol. 2012;22(4):265–71.
13. OECD (2022), Elderly population (indicator). https://doi.org/10.1787/8d805ea1-en (Last accessed on 03 September 2022).
14. Orimo H, Ito H, Suzuki T, et al. Reviewing the definition of ‘elderly’. Geriatr Gerontol Int. 2006;6(3):149–58.
15. Caterino JM, Valsek T, Wernan HA. Identification of an age cutoff for increased mortality in patients with elderly trauma. Am J Emerg Med. 2010;28(2):151–8.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457–81.
17. Cox DR, Oakes D. Analysis of survival data. London: Chapman Hall; 1984.
18. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27, 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
19. Oken MM, Creech RH, Torrey DC, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55.
20. Herskovic A, Martz K, Al Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.
21. Nienhueser H, Kunzmann R, Sisic L, et al. Surgery of gastric cancer and esophageal cancer: does age matter? J Surg Oncol. 2015;112(4):387–95.
22. Camero A, D’Journo XB, Ouattara M, et al. Adenocarcinoma of the esophagus and esophagogastric junction in patients older than 70 years: results of neoadjuvant radiochemotherapy followed by transthoracic esophagectomy. J Visc Surg. 2012;149(3):e203–10.
23. Schmidt T, Sicis L, Blank S, et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophageal carcinomas. Br J Cancer. 2014;110(7):1712–20. https://doi.org/10.1038/bjc.2014.94.
24. Raul A, Portale G, Castoro C, et al. Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol. 2007;14(11):3243–50.
25. Bollschweiler E, Plum P, Monig SP, et al. Current and future treatment options for esophageal cancer in the elderly. Expert Opin Pharmacother. 2017;18(10):1001–10.
26. Lu X, Wu H, Wang J, et al. Short- and long-term outcomes of definitive chemoradiotherapy in patients with esophageal carcinoma aged ≥75 years. Mol Clin Oncol. 2014;2(2):297–301.
27. Trumper M, Ross PJ, Cunningham D, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced
oesophago-gastric cancer: a pooled analysis of three clinical trials. Eur J Cancer. 2006;42(7):827–34.
28. Song T, Zhang X, Fang M, et al. Concurrent chemoradiotherapy using paclitaxel plus cisplatin in the treatment of elderly patients with esophageal cancer. Onco Targets Ther. 2015;8:3087–94.
29. Zhao L, Zhou Y, Pan H, et al. Radiotherapy alone or concurrent chemoradiation for esophageal squamous cell carcinoma in elderly patients. J Cancer. 2017;8(16):3242–50.
30. Paul G, Bohle W, Zoller W. Risk factors for the development of esophagorespiratory fistula in esophageal cancer. J Gastrointestin Liver Dis. 2019;28(3):265–70.
31. Xu Y, Cui H, Dong T, et al. Integrating clinical data and attentional CT imaging features for esophageal fistula prediction in esophageal cancer. Front Oncol. 2021;11:688706.
32. Münch S, Pigorsch SU, Feith M, et al. Comparison of neoadjuvant chemoradiation with carboplatin/paclitaxel or cisplatin/5-fluorouracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol. 2017;12:182.
33. Münch S, Pigorsch SU, Devečka M, et al. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluorouracil in patients with squamous cell carcinoma of the esophagus. Radiat Oncol. 2018;13:139.
34. Qu XM, Biagi JJ, Hopman WM, et al. Shifting practice in definitive chemoradiation for localized esophageal cancer. Curr Oncol. 2017;24(5):e379–87.
35. Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25(3):638–43.
36. Blom RL, Sosef MN, Nap M, et al. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma. Dis Esophagus. 2014;27(4):380–7.
37. Verma V, Haque W, Zheng D, et al. Patterns of care and outcomes of elderly esophageal cancer patients not meeting age-based criteria of the CROSS trial. Am J Clin Oncol. 2019;42(1):67–74.
38. Haefner MF, Lang K, Verma V, et al. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer. Strahlenther Onkol. 2018;194:116–24.
39. Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.
40. Qiu C, Zhang W, Wang F, et al. Metastasis patterns and prognosis of elderly patients with esophageal adenocarcinoma in stage IVB: a population-based study. Front Oncol. 2021;11:625720.
41. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013;86(5):885–91.
42. Mantziari S, Teixeira Farinha H, Bouygues V, et al. Esophageal cancer in elderly patients, current treatment options and outcomes; a systematic review and pooled analysis. Cancers. 2021;13(9):2104.
43. Inturnullo E, Moons J, Nafteux P, et al. Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years. Eur J Cardiothorac Surg. 2008;33(6):1096–104.
44. Morita M, Egashira A, Yoshida R, et al. Esophageal cancer in patients 80 years of age and older with carcinoma of the thoracic esophagus. J Gastroenterol. 2008;43(5):345–51.
45. Alexiou C, Begg D, Salama FD, et al. Surgery for esophageal cancer in elderly patients: the view from Nottingham. J Thorac Cardiovasc Surg. 1998;116(4):545–53.
46. Matsumoto Y, Kimura K, Zhou Q, et al. Treatments and outcomes of older patients with esophageal cancer: comparison with younger patients. Mol Clin Oncol. 2019;11(4):383–9.
47. Prythcherh DR, Whiteley MS, Higgins B, et al. POSSUM and Portsmouth POSSUM for predicting mortality. Physiological and operative severity score for the enumeration of mortality and morbidity. Br J Surg. 1998;85(9):1217–20.
48. Tekkis PP, McCulloch P, Poloniecki JD, et al. Risk-adjusted prediction of operative mortality in oesophagogastric surgery with O-POSSUM. Br J Surg. 2004;91(3):288–95.
49. Steyerberg EW, Neville BA, Koppert LB, et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol. 2006;24(26):4277–84.
50. D’Journo XB, Boulate D, Fournad A, et al. Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer [published correction appears in JAMA Surg. 2021 Sep;11:569(0):894]. JAMA Surg. 2021;156(9):836-845.
51. Deschamps C, Nichols FC 3rd, Cassivi SD, et al. Long-term function and quality of life after esophageal resection for cancer and Barrett’s. Surg Clin North Am. 2005;85(3):649–56.
52. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):733–46.
53. Hirpara DH, Kidane B, Rogalla P, et al. Frailty assessment prior to thoracic surgery for lung or esophageal cancer: a feasibility study. Support Care Cancer. 2019;27(4):1535–40.
54. Hamaker ME, Jonker JM, de Rooij SE, et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012;13(10):e437–44.
55. Rahimy E, Koong A, Toesca D, et al. Outcomes and tolerability of definitive and preoperative chemoradiation in elderly patients with esophageal cancer: a retrospective institutional review. Adv Radiat Oncol. 2020;5(6):1188–96.
56. Rippetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(4 Suppl 2):18–24.
57. Münch S, Aichmeier S, Hapfelmeyer A, et al. Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT. Strahlenther Onkol. 2016;192(10):722–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.